Advance your expertise in Cell & Gene Therapy (CGT) / Advanced Therapy Medicinal Products (ATMPs) with our specialised training programmes. From CMC and manufacturing to regulatory strategy and early development our courses equip professionals to lead in this fast-evolving field.
People Choose Educo Every Year
From 180 Different Companies
We Deliver Over 100 Courses Every Year
We Achieve 97% Positive Feedback
We support manufacturing, quality, process and analytical leaders to improve the technical skills and knowledge of their employees, so they are equipped to overcome challenges and meet business objectives. Working together, we design and deliver technical training courses that align with your learning requirements and business goals. For more information about how we can support your team please get in touch.
Could your manufacturing team benefit from any of the courses listed above? Or maybe a topic which is not highlighted? We would be happy to discuss your objectives and see how we might be able to help.
In our ATMP portfolio topics include:
Our training courses are ideal for:
The development of cell and gene therapies requires a deep understanding of both cutting-edge science and evolving regulatory frameworks. Our training programmes span vector design, manufacturing, regulatory strategy, clinical development, and lifecycle management. We cover regulatory expectations such as EMA ATMP regulation, FDA gene & cell therapy guidances, and global harmonisation trends.
Learn the nuances of viral (AAV, lentivirus) and non-viral gene delivery systems, cell engineering, expansion, purification, and downstream processing. Explore how to develop manufacturing strategies, scale processes, and manage comparability and control for ATMPs.
Because CGT products often require long-term monitoring, we emphasize topics like biodistribution, transgene integration, immunogenicity, vector shedding, durability, and safety follow-up. You’ll also explore how to design clinical endpoints, manage follow-up studies, and align with agency expectations.
Address regulatory pathways (IMPD, BLA, MAA for ATMPs), expedited designations, post-approval changes, and regulatory reporting obligations. Understand how to evolve your strategy as the product moves from preclinical through late clinical to commercial lifecycle.